Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

SIMPLE SUMMARY: The 21-gene Oncotype DX Breast Recurrence Score(®) assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2−) in Early Breast Cancer (EBC). The KARMA Dx study evaluated the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Llombart-Cussac, Antonio, Anton-Torres, Antonio, Rojas, Beatriz, Andrés, Raquel, Martinez, Noelia, Rodríguez, César A., Marin, Sara, Puértolas, Teresa, González, Alejandro Falcón, Fernández-Murga, María Leonor, Hagen, Carlos, Ruiz-Borrego, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001004/
https://www.ncbi.nlm.nih.gov/pubmed/36900321
http://dx.doi.org/10.3390/cancers15051529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001004/
https://www.ncbi.nlm.nih.gov/pubmed/36900321
http://dx.doi.org/10.3390/cancers15051529

Ejemplares similares